KEZAR LIFE SCIENCES INC. overview

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen Roth Henig, M.D., Chief Medical Officer, will participate on the Kidney Disease/Fibrosis Panel at the Cowen 42 nd Annual Health Care Conference. The panel will be held on Wednesday, March 9, 2022, at 2:10 p.m. ET. A live webcast of the panel will be available on the “Events & Presentations”...

Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its second quarter 2020 financial results and corporate highlights. “Our excitement continues to build around the novel mechanism of KZR-616 and supports our conviction that targeting master regulators of cellular function – like the immunoproteasome – can benefit patients in need,” said John...

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the pricing of an underwritten public offering of 7,590,909 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 909,091 shares of its common stock at an exercise price of...

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the common stock in the offering will be sold by Kezar. The offering is subject to market and other conditions, and...

Two of two patients with Lupus Nephritis saw greater than 50% reduction in proteinuria KZR-616 demonstrates improvement on exploratory efficacy measures across seven measures of disease activity Step-up dosing drives positive safety and tolerability profile SOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune...

SOUTH SAN FRANCISCO, May 28, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of its executive team will participate in a Fireside Chat during the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30pm EDT. The presentation will be webcast live and may be accessed at the “Events &...

SOUTH SAN FRANCISCO, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced presentations during upcoming major scientific conferences. “Kezar’s unique ability to translate novel science into viable treatment options is underscored by the selection of three abstracts featuring data from both of...

Noreen R. Henig, MD appointed as Chief Medical Officer Additional data from the ongoing Phase 1b portion of the MISSION study to be presented before the end of Q2 2020 IND submission for KZR-261, a first-in-class protein secretion inhibitor, is on track for Q1 2021 Cash, cash equivalents and marketable securities of $123 million as of March 31, 2020 SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and...